Updated Data From Alloshrink Phase I First-Inhuman Study Evaluating Cyad-101, An Innovative Non-Gene Edited Allogeneic Car-T In Mcrc.

Hans Prenen,Jeroen Dekervel,Alain Hendlisz,Sébastien Anguille,Ahmad Awada,Emilie Cerf,Caroline Lonez,Eytan Breman,Marie-Sophie Dheur,Erik Alcantar-Orozco,David Edward Gilham,Anne Flament,Frederic Lehmann,Eric Van Cutsem

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 17|浏览8

暂无评分

摘要

74Background: CYAD-101 is a first-in-class, non-gene edited allogeneic CAR T-cell product that combines the broad breadth of tumor targeting of the NKG2D-based chimeric antigen receptor (CAR) with ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要